The acyltransferase (AT) domain in module 4 of the erythromycin polyketide synthase (PKS) was substituted with an AT domain from the rapamycin PKS module 2 in order to alter the substrate specificity from methylmalonyl-CoA to malonyl-CoA. The resulting strain produced 6-desmethyl erythromycin D as the predominant product. This AT domain swap completes the library of malonyl-CoA AT swaps on the erythromycin PKS and reinforces PKS engineering as a robust and generic tool. 
The acyltransferase (AT) domain in module 4 of the erythromycin polyketide synthase (PKS) was substituted with an AT domain from the rapamycin PKS module 2 in order to alter the substrate specificity from methylmalonyl-CoA to malonyl-CoA. The resulting strain produced 6-desmethyl erythromycin D as the predominant product. This AT domain swap completes the library of malonyl-CoA AT swaps on the erythromycin PKS and reinforces PKS engineering as a robust and generic tool.
Erythromycin A (1) and the derived semi-synthetic, second generation macrolides such as azithromycin (Zithromax) and clarithromycin (Biaxin) (5) (Figure 1 ) have been important antibiotics for the treatment of respiratory tract infections for many years. However, the rise in numbers of macrolide resistant pathogens has greatly increased the need to develop new derivatives of these highly effective molecules that combine both a better understanding of the different resistance mechanisms with novel approaches to changing the nature of the chemistry around the molecule, while maintaining the excellent safety and tolerability profile of the erythromycin series. In addition to utilising conventional chemical approaches, the well-established modularity of Type I polyketide synthase (PKS) multienzyme complexes readily lends itself to the use of genetic engineering to develop non-natural analogues of commercially valuable products1). Of the large numbers of modular PKS clusters sequenced during the past decade the erythromycin PKS (DEBS) is the most intensively studied and has remained the best model system for the demonstration of key technologies. A model system derived from the DEBS was used to demonstrate the first PKS heterologous AT domain swap, generating a desmethyl triketide lactone by replacing the methylmalonyl-CoA specific AT from module 1 with a malonyl-CoA specific AT from the rapamycin PKS2). Subsequent work in this PKS system has replaced the ATs from the loading module3) and the extension modules 2, 3, 5, and 6 in a similar manner4-6) incompatibility of the particular domains used, or limitations of product analysis and detection rather than an impossibility of making a productive swap at this point. Desire to produce this compound has remained strong;
REEVES and co-workers having failed to develop an AT replacement strategy for production of the 6-desmethyl compound report the use of a site-directed mutagenesis strategy which produces the aglycone 6-deoxy-6-desmethyl erythronolide B in a mixture with 6-deoxy erythronolide B (6DEB)7). Here, we report the construction of a strain containing a hybrid DEBS PKS in which the AT4 has been replaced by the AT2 derived from the rapamycin PKS cluster and its use to produce a glycosylated and biologically active antibiotic 6-desmethyl erythromycin D (9).
Results

Construction of Recombinant Strains
Two strategies were employed to produce the desired strains.
In the first, conventional gene replacement methodologies were used to substitute DEBS AT4 by RAP AT2 in the wild type Saccharopolyspora erythraea NRRL 2338 (Figures 2 and 3 ). The protein splice sites chosen to flank the donor AT were the same as those used by OLIYNYK et al.2), although recombinant strains utilising a different set of splice sites and an alternative donor AT also produced the expected compound ( Figure 3 ). The design of the constructs incorporated a cassette system that allowed us to introduce ATs from multiple donors in a relatively simple manner, although as our initial constructs were functional, it was not actually necessary to test a large number of further ATs. In the second strategy the replacement cassette containing the heterologous AT described above was excised and used to substitute the equivalent region in a plasmid containing EryAI, EryAII and EryAIII genes under the control of the actI/actII-Orf4 promoter-activator system of Streptomyces coelicolor. This plasmid pHP020 was then introduced into the strain JC2 which is deleted of the almost the entire PKS region9), using the remaining TE portion of the PKS as a region of homology for integration (Figure 2 ).
Characterisation of Metabolites
Recombinant strains made by replacement and single crossover strategies were grown under standard production Left hand side of diagram shows the cassette plasmid pHP012 used to introduce multiple ATs into AT4. Top of diagram shows the double crossover event required in the S. erythraea chromosome to replace the AT4 domain using replacement plasmid pHP014. Bottom of diagram shows the conversion of the replacement cassette into pHP020, containing the modified PKS under the actI/actII-Orf4 promoter-activator system and subsequent integration into S. erythraea JC2 chromosome. M=MscI, Sm=SmaI, A=AvrII, Sf=SfiI. cladinose moiety m/z=158), indicated that the structure was most likely 6-desmethyl erythromycin B (7). Peaks consistent with the presence of 6-desmethyl erythromycin A and C were also identified.
Structure Determination
To verify the structure, compound 9 (4.2mg) was isolated from a 14 litres fermentation of S. erythraea JC2/pHP020 (BIOT0861) in Ery-P medium10 Biological Activity 6-Desmethyl erythromycin D had comparable antibacterial activity to erythromycin D suggesting that the methyl group at the 6-position does not play a significant role in antibiotic activity. As anticipated, 6-desmethyl erythromycin D showed no activity against macrolideresistant strains (Table 2) . Discussion 6-Desmethyl erythromycin D (9) was isolated from a strain in which the natural acyltransferase of DEBS module 4, which specifies methylmalonyl-CoA, was replaced with an acyltransferase specifying malonyl-CoA. While AT domain replacements have been shown to produce the desired products in DEBS modules 1, 2, 3, 5 and 64-6), successful substitution of this particular domain by malonyl-CoA specific ATs has evaded a number of researchers4,7). The reasons for this are unclear but it has been postulated that the inserted domain might cause the PKS complex to misfold, or alternatively that the modified polyketide chain cannot be recognised by downstream domains of the PKS4,7). On the other hand products have been produced when AT4 has been substituted by an AT specific for the ethylmalonyl-CoA extender units8) although these ATs tend to be more similar to methylmalonyl-CoA ATs and are therefore less likely to affect the intrinsic PKS structure. We also designed a plasmid system that would allow multiple AT domain donors to be tested in an efficient manner. In addition to a conventional, but slower, replacement (double crossover) strategy the design of the system also included the use of a plasmid containing the entire erythromycin PKS. Following manipulation of the PKS, this plasmid was introduced into S. erythraea JC2 (which has been deleted of almost the entire PKS9)), using the TE as a homology region for integration. This approach gave us the ability to construct multiple recombinant strains by single integration, and enabled us to take advantage of the enhanced polyketide production levels we have observed from PKS expressed from the actI/actII promoteractivator system in this strain.
The demonstration that substituting the natural acyl transferase domain of module 4 with an AT that specifies propose that the failure of their heterologous AT swaps in module 4 was due to incompatibility between the inserted domain and module 4 rather than the inability of the PKS to process the desmethyl-pentaketide by using a heterologous AT capable of incorporating both malonyl-and methylmalonyl-CoA, although these authors did not do extensive trials of alternative domain splice sites. The production of the 6-desmethyl-6DEB as a mixture using a site-directed mutagenesis strategy to alter AT specificity is a further indication that the PKS can tolerate the desmethyl pentaketide.
One of the important features of our experiments was to produce fully glycosylated, and hence biologically active modified erythromycins rather than a simple aglycone template. It is the post-PKS processing steps such as glycosylation, hydroxylation or methylation that give these molecules their biological activity, and it can be difficult to judge which of these reactions will be affected by changes contrast other sugar methyl transferases show a broad tolerance to the nature of the aglycone18). Perversely, our experiments were probably aided by our strong belief that we should concentrate on the production of processed, and hence biologically active, erythromycins rather than the simple aglycone core. The presence of an amino sugar in glycosylated products enhances detection limits through protonation and improved ionisation in the electrospray MS source. Low levels of erythromycin A can be detected (2-5% of the desmethyl compounds), showing the tight specificity of the introduced domain. This is in contrast to the switch in AT4 substrate specificity by introducing site-directed mutations which at best produced approximately equal amounts of the 6DEB or 6-desmethyl-6DEB7 Fermentation of S. erythraea JC2/pHP020 S. erythraea JC2/pHP020 was cultured from a frozen vegetative working stock (1:1, TSB culture: cryopreservative; cryopreservative was 20% glycerol: 10% lactose w/v in distilled water). A primary pre-culture was grown in TSB (50ml in 250ml flask) shaken at 250rpm v/v) a secondary pre-culture of TSB (400ml in a 2 litre flask), which was cultured under the same conditions for a further two days. Twelve litres of Ery-P production medium10) was inoculated with the secondary pre-culture (5% v/v) and allowed to ferment in a 20 litre stirred rate of 6 litres/minute.
Isolation of 6-Desmethyl Erythromycin D (9) After 5 days the fermentation broth of S. erythraea JC2/pHP020 was clarified by centrifugation, the supernatant adjusted to pH -9.5 with sodium hydroxide and then stirred with Amberlite XAD-16 resin (100g) at room temperature. After 30 minutes the resin was isolated by centrifugation, washed with water (200ml) and then repeated twice more, the resulting methanol eluates combined and the solvent removed under reduced pressure to yield an aqueous solution (-50ml) . This was diluted with water (150ml) and extracted with ethyl acetate removed to yield a brown oil (6.9g). The oil was partitioned between acetic acid/sodium acetate (1:1, 100 ml, pH 5) and ethyl acetate (100ml), and the solvent removed to leave a concentrated extract (0.5g).
The extract was purified by chromatography over mm), eluting at a flow rate of 21ml/minute with a linear gradient of acetonitrile: 20mM ammonium acetate (25%-75% over 19 minutes). Fractions were collected every 30 seconds and assayed by LC-MS. Significant loss was tolerated at this stage to ensure purity of the final product. Those containing 6-desmethyl erythromycin D (9) were combined and the solvent removed. This was then concentrated using an IsoElute ENV+ cartridge (200mg), ml) to yield 6-desmethyl erythromycin D (9) as an amorphous white solid (4.2mg). The presence of 6-desmethyl erythromycin A, B, C (6, 7, 8) 
